Big Pharma Split Past Earnings Performance
Past criteria checks 0/6
Big Pharma Split's earnings have been declining at an average annual rate of -10.5%, while the Capital Markets industry saw earnings growing at 7.4% annually. Revenues have been declining at an average rate of 1% per year.
Key information
-10.5%
Earnings growth rate
-12.8%
EPS growth rate
| Capital Markets Industry Growth | 12.1% |
| Revenue growth rate | -1.0% |
| Return on equity | -4.1% |
| Net Margin | -201.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Big Pharma Split makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -1 | 1 | 0 |
| 30 Sep 23 | 1 | 0 | 1 | 0 |
| 30 Jun 23 | 3 | 0 | 1 | 0 |
| 31 Mar 23 | 5 | 1 | 1 | 0 |
| 31 Dec 22 | 7 | 2 | 1 | 0 |
| 30 Sep 22 | 7 | 3 | 1 | 0 |
| 30 Jun 22 | 7 | 4 | 1 | 0 |
| 31 Mar 22 | 6 | 4 | 1 | 0 |
| 31 Dec 21 | 6 | 4 | 1 | 0 |
| 30 Sep 21 | 4 | 4 | 1 | 0 |
| 30 Jun 21 | 2 | 3 | 1 | 0 |
| 31 Mar 21 | 2 | 2 | 1 | 0 |
| 31 Dec 20 | 1 | 0 | 0 | 0 |
| 30 Sep 20 | 3 | 1 | 0 | 0 |
| 30 Jun 20 | 4 | 2 | 0 | 0 |
| 31 Mar 20 | 3 | 2 | 1 | 0 |
| 31 Dec 19 | 2 | 3 | 1 | 0 |
| 30 Sep 19 | 3 | 2 | 1 | 0 |
| 30 Jun 19 | 3 | 2 | 1 | 0 |
| 31 Mar 19 | 5 | 2 | 1 | 0 |
| 31 Dec 18 | 6 | 2 | 1 | 0 |
| 31 Dec 17 | 1 | -4 | 8 | 0 |
Quality Earnings: PRM.PRA is currently unprofitable.
Growing Profit Margin: PRM.PRA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PRM.PRA is unprofitable, and losses have increased over the past 5 years at a rate of 10.5% per year.
Accelerating Growth: Unable to compare PRM.PRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PRM.PRA is unprofitable, making it difficult to compare its past year earnings growth to the Capital Markets industry (7.2%).
Return on Equity
High ROE: PRM.PRA has a negative Return on Equity (-4.07%), as it is currently unprofitable.